EMFRET ANALYTICS
Our most widely used research products
Mouse platelet depletion with reagent R300
- By targeting GPIbα (CD42b) with a mixture of monoclonal IgGs, R300 induces profound and sustained Fc-independent platelet depletion in mice.
- Easy to administer either i.v. or i.p.
- Platelet depletion is frequently used to study the general role of platelets in (patho-) physiology.
In vivo imaging of circulating mouse platelets
- Fluorescent antibody derivatives directed against GPIbβ (CD42c).
- Available conjugated to highly fluorescent and photostable DyLight488 or DyLight650.
- Stable and non-cytotoxic labeling of platelets and bone marrow-resident megakaryocytes.
Two-Parameter Analysis of Platelet Activation in Flow Cytometry
- Detects two activation markers in one step –
P-Selectin exposure and inside-out activation of GPIIb/IIIa (CD41/CD61). - D200 Double Staining Kit
Analysis of mouse GPVI function in vitro and in vivo with mAb JAQ1
- Functionally inhibits GPVI in mouse platelets in vitro.
- Immunodepletes GPVI in mice resulting in a GPVI-knockout-like phenotype.
- Cross-reacts with human GPVI.
- Suitable for immunoprecipitation, immunohistochemical analysis of acetone-fixed frozen sections, immunofluorescent staining, and Western blot analysis.
EMFRET ANALYTICS
Our Science
Platelets are central regulators of vascular integrity, playing a key role not only in hemostasis and thrombosis but also in inflammation and immune responses. Their complex involvement in health and disease—particularly within the emerging field of thrombo-inflammation—has reshaped our understanding of cardiovascular and systemic disorders.
Advancing this knowledge requires models and tools that capture these processes in their full biological context. By enabling in vivo analysis and precise molecular investigation, new research approaches are opening pathways toward a deeper mechanistic understanding and the development of safer, next-generation therapies.
Thrombo-Inflammation Insights
Precision Molecular Tools
Next-Gen Therapies
In Vivo Analysis
Thrombo-Inflammation Insights
Precision Molecular Tools
Next-Gen Therapies
In Vivo Analysis
EMFRET ANALYTICS
Our Pipeline
Our pipeline represents the full spectrum of therapies in development.
From early research to potential approval, it defines our path forward.
EMFRET ANALYTICS
About EMFRET
Emfret Analytics is a German biotech company pioneering innovative tools for platelet research. Its globally unique antibody portfolio enables precise molecular insights and has become a benchmark in over 600 laboratories worldwide.
UPDATE
Latest News
Boehringer Ingelheim and Emfret Analytics sign collaboration...
Boehringer Ingelheim and Emfret Analytics sign collaboration and license agreement to advance a first-in-class antibody therapy for acute ischemic stroke
Eibelstadt, Germany – 30.03.2026
Emfret Analytics...
State-of-the-art lecture on GPVI targeting at the GTH Congress 2026 in Bonn, Germany.
State-of-the-art lecture on GPVI targeting at the GTH Congress 2026 in Bonn, Germany. Emfret´s lead candidate EMA601 underscores its high potential as first-in-class GPVI inhibitor.
Eibelstadt/Würzburg/Bonn...
EMA601: Preclinical development of the humanized anti-GPVI Fab published in the European Heart Journal.
EMA601: Preclinical development of the humanized anti-GPVI Fab published in the European Heart Journal. A safe lead candidate with unprecedented anti-thrombotic and anti-thrombo-inflammatory potency
Eibelstadt/Würzburg,...
EMFRET presents the anti-GPVI lead candidate EMA601...
Eibelstadt/Würzburg/Bangkok – 22 June 2024
EMFRET Analytics presented for the first time its humanized anti-platelet glycoprotein VI (GPVI) Fab fragment EMA601 in the Plenary Late-Breakthrough Session...
CONNECT
Get in touch
-
EMFRET Analytics GmbH & Co. KG
Am Morgenroth 6
97246 Eibelstadt
Germany - service@emfret.com